ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

Background: ABX464 (obefazimod) is a small molecule that upregulates a single microRNA (miR-124) in immune cells and reduces the production of various inflammatory cytokines and chemokines. Objective: We assessed the efficacy and safety of the standard of care (SoC) plus oral obefazimod (SoC plus AB...

Full description

Bibliographic Details
Main Authors: Pedro Giavina-Bianchi, MD, PhD, Eric Cua, MD, Karine Risso, MD, Véronique Mondain, MD, Anaïs Vissian, MSc, Cécile Joie, MSc, Philippe Pouletty, MD, Paul Gineste, PharmD, Hartmut J. Ehrlich, MD, PhD, Jorge Kalil, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:Journal of Allergy and Clinical Immunology: Global
Subjects:
ABX464
obefazimod
miR-124
COVID-19
Online Access:http://www.sciencedirect.com/science/article/pii/S2772829323000656

Internet

http://www.sciencedirect.com/science/article/pii/S2772829323000656

Similar Items